Evaluation of the CCK-4 model as a challenge paradigm in a population of healthy volunteers within a proof-of-concept study

被引:40
作者
Eser, Daniela
Schuele, Cornelius
Baghai, Thomas
Floesser, Anette
Krebs-Brown, Axel
Enunwa, Michaela
de la Motte, Stephan
Engel, Rolf
Kucher, Klaus
Rupprecht, Rainer
机构
[1] Univ Munich, Dept Psychiat & Psychotherapy, D-80336 Munich, Germany
[2] Novartis Pharma AG, Exploratory Clin Dev, Basel, Switzerland
[3] Novartis Pharma AG, Biostat, Basel, Switzerland
[4] Harrison Clin Res Inst, Munich, Germany
关键词
CCK-4; panic disorder; anxiety; challenge paradigm; proof-of-concept;
D O I
10.1007/s00213-007-0738-7
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Rationale Experimental panic induction with cholecystokinin-tetrapeptide (CCK-4) has been established as a model to study the pathophysiology of panic disorder and might serve as a tool to asses the antipanic potential of novel anxiolytic compounds. However, assessment of CCK-4-induced panic does not follow consistent rules. Objectives To provide a basis for the use of the CCK-4 model in proof-of-concept studies, we investigated CCK-4-induced panic according to different criteria in 85 healthy volunteers who underwent a CCK-4 bolus injection. Methods We assessed panicker/non-panicker ratios according to different panic criteria and explored whether differences in cardiovascular and neuroendocrine responses to CCK- 4 paralleled subjective panic responses. Subjective panic responses were measured with the Acute Panic Inventory (API) and the Panic Symptom Scale (PSS). Heart rate, blood pressure, adrenocorticotropic hormone (ACTH) and cortisol were assessed concomitantly. Results The API-derived panic rate was 10.6% higher than that derived from the PSS. CCK-4 induced an increase in heart rate, systolic blood pressure and ACTH/cortisol plasma levels, which did not differ between panickers and non- panickers. Conclusions The panic criterion applied appears to be of major importance for the panic rate achieved, whereas CCK-4-induced cardiovascular and hormonal alterations are not valuable as an objective '' read out ''. The CCK-4 challenge might serve as a useful model to study putative anxiolytic effects of novel compounds during the early phase of drug development if the challenge procedure is carried out according to strictly comparable conditions.
引用
收藏
页码:479 / 487
页数:9
相关论文
共 44 条
  • [1] Cognitive modulation of the endocrine stress response to a pharmacological challenge in normal and panic disorder subjects
    Abelson, JL
    Liberzon, I
    Young, EA
    Khan, S
    [J]. ARCHIVES OF GENERAL PSYCHIATRY, 2005, 62 (06) : 668 - 675
  • [2] Dose response of adrenocorticotropin and cortisol to the CCK-B agonist pentagastrin
    Abelson, JL
    Liberzon, I
    [J]. NEUROPSYCHOPHARMACOLOGY, 1999, 21 (04) : 485 - 494
  • [3] Ackenheil M., 1999, MINI INT NEUROPSYCHI
  • [4] Cholecystokinin tetrapeptide-induced calcium mobilization in T cells of patients with panic disorder, major depression, or schizophrenia
    Akiyoshi, J
    Isogawa, K
    Tsutsumi, T
    Kasturagi, S
    Kohno, K
    Furuta, M
    Yamamoto, Y
    Yamada, K
    Fujii, I
    [J]. BIOLOGICAL PSYCHIATRY, 1997, 42 (02) : 151 - 154
  • [5] Emotional and cognitive factors connected with response to cholecystokinin tetrapeptide in healthy volunteers
    Aluoja, A
    Shlik, J
    Vasar, V
    Kingisepp, PH
    Jagomagi, K
    Vasar, E
    Bradwejn, J
    [J]. PSYCHIATRY RESEARCH, 1997, 66 (01) : 59 - 67
  • [6] THE DISTRIBUTION OF CHOLECYSTOKININ IMMUNOREACTIVITY IN THE CENTRAL NERVOUS-SYSTEM OF THE RAT AS DETERMINED BY RADIOIMMUNOASSAY
    BEINFELD, MC
    MEYER, DK
    ESKAY, RL
    JENSEN, RT
    BROWNSTEIN, MJ
    [J]. BRAIN RESEARCH, 1981, 212 (01) : 51 - 57
  • [7] Bradwejn J, 1998, AM J PSYCHIAT, V155, P280
  • [8] BRADWEJN J, 1991, ARCH GEN PSYCHIAT, V48, P603
  • [9] BRADWEJN J, 1994, ARCH GEN PSYCHIAT, V51, P486
  • [10] THE CHOLECYSTOKININ HYPOTHESIS OF ANXIETY AND PANIC DISORDER
    BRADWEJN, J
    KOSZYCKI, D
    [J]. CHOLECYSTOKININ, 1994, 713 : 273 - 282